Immunization with plasmid DNA encoding the hemagglutinin and the nucleoprotein confers robust protection against a lethal canine distemper virus challenge

Vaccine ◽  
2004 ◽  
Vol 22 (27-28) ◽  
pp. 3642-3648 ◽  
Author(s):  
Lotte Dahl ◽  
Trine Hammer Jensen ◽  
Elisabeth Gottschalck ◽  
Peter Karlskov-Mortensen ◽  
Tove Dannemann Jensen ◽  
...  
Keyword(s):  
Plasmid Dna ◽  
Canine Distemper Virus ◽  
Canine Distemper ◽  
Dna Encoding ◽  
Virus Challenge

scholarly journals Probing Morbillivirus Antisera Neutralization Using Functional Chimerism between Measles Virus and Canine Distemper Virus Envelope Glycoproteins

Viruses ◽  
2019 ◽  
Vol 11 (8) ◽  
pp. 688 ◽  
Author(s):  
Miguel Angel Muñoz-Alía ◽  
Stephen J. Russell
Keyword(s):  
Neutralizing Antibodies ◽  
Measles Virus ◽  
Canine Distemper Virus ◽  
Reverse Genetics ◽  
Canine Distemper ◽  
Virus Envelope ◽  
Live Virus ◽  
Virus Challenge ◽  
Virus Attachment ◽  
Globular Head

Measles virus (MeV) is monotypic. Live virus challenge provokes a broadly protective humoral immune response that neutralizes all known measles genotypes. The two surface glycoproteins, H and F, mediate virus attachment and entry, respectively, and neutralizing antibodies to H are considered the main correlate of protection. Herein, we made improvements to the MeV reverse genetics system and generated a panel of recombinant MeVs in which the globular head domain or stalk region of the H glycoprotein or the entire F protein, or both, were substituted with the corresponding protein domains from canine distemper virus (CDV), a closely related morbillivirus that resists neutralization by measles-immune sera. The viruses were tested for sensitivity to human or guinea pig neutralizing anti-MeV antisera and to ferret anti-CDV antisera. Virus neutralization was mediated by antibodies to both H and F proteins, with H being immunodominant in the case of MeV and F being so in the case of CDV. Additionally, the globular head domains of both MeV and CDV H proteins were immunodominant over their stalk regions. These data shed further light on the factors constraining the evolution of new morbillivirus serotypes.

Vaccination of puppies with a lipid-formulated plasmid vaccine protects against a severe canine distemper virus challenge

Vaccine ◽  
2003 ◽  
Vol 21 (11-12) ◽  
pp. 1099-1102 ◽  
Author(s):  
Laurent Fischer ◽  
Jean Philippe Tronel ◽  
Jules Minke ◽  
Simona Barzu ◽  
Philippe Baudu ◽  
...  
Keyword(s):  
Canine Distemper Virus ◽  
Canine Distemper ◽  
Virus Challenge ◽  
Plasmid Vaccine

Vaccination of puppies born to immune dams with a canine adenovirus-based vaccine protects against a canine distemper virus challenge

Vaccine ◽  
2002 ◽  
Vol 20 (29-30) ◽  
pp. 3485-3497 ◽  
Author(s):  
Laurent Fischer ◽  
Jean Philippe Tronel ◽  
Camilla Pardo-David ◽  
Patrick Tanner ◽  
Guy Colombet ◽  
...  
Keyword(s):  
Canine Distemper Virus ◽  
Canine Distemper ◽  
Virus Challenge

scholarly journals DNA vaccines encoding proteins from wild-type and attenuated canine distemper virus protect equally well against wild-type virus challenge

2012 ◽  
Vol 157 (10) ◽  
pp. 1887-1896 ◽  
Author(s):  
Line Nielsen ◽  
Trine Hammer Jensen ◽  
Birte Kristensen ◽  
Tove Dannemann Jensen ◽  
Peter Karlskov-Mortensen ◽  
...  
Keyword(s):  
Canine Distemper Virus ◽  
Dna Vaccines ◽  
Wild Type Virus ◽  
Type Virus ◽  
Canine Distemper ◽  
Wild Type ◽  
Virus Challenge

scholarly journals Intratumoral Canine Distemper Virus Infection Inhibits Tumor Growth by Modulation of the Tumor Microenvironment in a Murine Xenograft Model of Canine Histiocytic Sarcoma

2021 ◽  
Vol 22 (7) ◽  
pp. 3578
Author(s):  
Federico Armando ◽  
Adnan Fayyad ◽  
Stefanie Arms ◽  
Yvonne Barthel ◽  
Dirk Schaudien ◽  
...  
Keyword(s):  
Tumor Microenvironment ◽  
Virus Infection ◽  
Tumor Growth ◽  
Canine Distemper Virus ◽  
Xenograft Model ◽  
Histiocytic Sarcoma ◽  
Oncolytic Viruses ◽  
Canine Distemper ◽  
Murine Xenograft Model ◽  
The Impact

Histiocytic sarcomas refer to highly aggressive tumors with a poor prognosis that respond poorly to conventional treatment approaches. Oncolytic viruses, which have gained significant traction as a cancer therapy in recent decades, represent a promising option for treating histiocytic sarcomas through their replication and/or by modulating the tumor microenvironment. The live attenuated canine distemper virus (CDV) vaccine strain Onderstepoort represents an attractive candidate for oncolytic viral therapy. In the present study, oncolytic virotherapy with CDV was used to investigate the impact of this virus infection on tumor cell growth through direct oncolytic effects or by virus-mediated modulation of the tumor microenvironment with special emphasis on angiogenesis, expression of selected MMPs and TIMP-1 and tumor-associated macrophages in a murine xenograft model of canine histiocytic sarcoma. Treatment of mice with xenotransplanted canine histiocytic sarcomas using CDV induced overt retardation in tumor progression accompanied by necrosis of neoplastic cells, increased numbers of intratumoral macrophages, reduced angiogenesis and modulation of the expression of MMPs and TIMP-1. The present data suggest that CDV inhibits tumor growth in a multifactorial way, including direct cell lysis and reduction of angiogenesis and modulation of MMPs and their inhibitor TIMP-1, providing further support for the concept of its role in oncolytic therapies.

scholarly journals Drivers of canine distemper virus exposure in dogs at a wildlife interface in Janos, Mexico

2021 ◽  
Vol 8 (1) ◽  
Author(s):  
Rocío Almuna ◽  
Andrés M. López‐Pérez ◽  
Rosa E. Sarmiento ◽  
Gerardo Suzán
Keyword(s):  
Canine Distemper Virus ◽  
Canine Distemper ◽  
Virus Exposure
Sign in / Sign up

Export Citation Format

Share Document